The type 1
insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have been increasingly recognized to drive the development of
malignancies, including
non-small cell lung cancer (NSCLC). This study aimed to investigate the effects of IGF-1R and its inhibitor,
AG1024, on the progression of
lung cancer. Tissue microarray and immunohistochemistry were employed to detect the expressions of
IGF-1 and IGF-1R in NSCLC tissues (n=198). Western blotting was used to determine the expressions of
IGF-1 and phosphorylated IGF-1R (p-IGF-1R) in A549 human lung
carcinoma cells, and MTT assay to measure cell proliferation. Additionally, the expressions of
IGF-1, p-IGF-1R and IGF-1R in a mouse model of
lung cancer were detected by Western blotting and real-time fluorescence quantitative polymerase chain reaction (FQ-PCR), respectively. The results showed that
IGF-1 and IGF-1R were overexpressed in NSCLC tissues. The expression levels of
IGF-1 and p-IGF-1R were significantly increased in A549 cells treated with
IGF-1 as compared to those treated with IGF-1+AG1024 or untreated cells. In the presence of
IGF-1, the proliferation of A549 cells was significantly increased. The progression of
lung cancer in mice treated with
IGF-1 was significantly increased as compared to the group treated with IGF-1+AG1024 or the control group, with the same trend mirrored in IGF-1/p-IGF-1R/IGF-1R at the
protein and/or
mRNA levels. It was concluded that
IGF-1 and IGF inhibitor
AG1024 promotes
lung cancer progression.